Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects
jRCT2080224066Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of luvadaxistat (7 cohorts), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-831, Pharmacokinetics of TAK-831 and 1 more. Started Sep 2018; status: completed.
02
Drugs
luvadaxistat
Beyond the preview
Go deeper on jRCT2080224066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224066.